Table 4. The clinicopathological parameters of BC patients, n = 73.
| Clinicopathological parameter | N (%) | |
|---|---|---|
| Age (year) | ≤ 45 | 23 (31.5) |
| > 45 | 50 (68.5) | |
| Menstrual status | Premenopausal | 39 (53.4) |
| Postmenopausal | 34 (46.6) | |
| Histological type | Invasive ductal carcinoma | 63 (86.3) |
| Invasive lobular carcinoma | 3 (4.1) | |
| Medullary carcinoma | 2 (2.7) | |
| Others | 5 (6.8) | |
| Tumor size | T1 | 9 (12.3) |
| T2 | 57 (78.1) | |
| T3 | 3 (4.1) | |
| T4 | 4 (5.5) | |
| Lymph node status | N0 | 30 (41.1) |
| N1 | 33 (45.2) | |
| N2 | 4 (5.5) | |
| N3 | 6 (8.2) | |
| Estrogen receptor | Positive | 36 (49.3) |
| Negative | 33 (45.2) | |
| No data | 4 (5.5) | |
| Progesterone receptor | Positive | 38 (52.1) |
| Negative | 31 (42.5) | |
| No data | 4 (5.5) | |
| HER2 | 0/+ | 51 (69.9) |
| ++ | 11 (15.1) | |
| +++ | 6 (8.2) | |
| No data | 5 (6.8) | |
| Molecular subtype | Luminal B | 45 (61.6) |
| Triple-negative | 18 (24.7) | |
| HER2-positive | 10 (13.7) | |
| Histological form | Unicentric | 50 (68.5) |
| Multicentric | 23 (31.5) | |
| Pathomorphosis | 1 rate | 21 (28.8) |
| 2 rate | 23 (31.5) | |
| 3 rate | 6 (8.2) | |
| 4 rate | 4 (5.5) | |
| No data | 19 (26.0) | |
| Grade | 1 rate | 2 (2.7) |
| 2 rate | 53 (72.6) | |
| 3 rate | 6 (8.2) | |
| No data | 12 (16.4) | |
| NAC regimen | CAX | 23 (31.5) |
| FAC | 36 (49.3) | |
| Taxotere | 14 (19.2) | |
| NAC response | Complete response | 5 (6.8) |
| Partial response | 40 (54.8) | |
| Stable disease | 20 (27.4) | |
| Progressive disease | 8 (11.0) | |
Abbreviations: NAC, neoadjuvant chemotherapy; CAX, Cyclophosphamide-Adriamycin-Xeloda; FAC, 5-Fluorourail-Adriamycin-Cyclophosphamide; HER2 testing is performed in accordance with American Society of Clinical Oncology/College of American Pathologists Guideline 2007 Recommendation [41].